«The biohybrid retina is a cell therapy for the reconstruction of the damaged retina by implanting healthy cells in the patient’s eye,» says Fivos Panetsos, director of the Neuro-computation and Neuro-robotics Group of the UCM and member of the Institute of Health Research of the Hospital Clínico San Carlos de Madrid (IdISSC).

The cells of the artificial retina adhere to very thin silk fibroin biofilms — a biomaterial 100% biocompatible with human tissue — and covered by a gel which protects them during eye surgery and allows them to survive during the time they need to get integrated with thesurrounding tissue after transplantation.

«The transplanted retina also contains mesenchymal cells that function as producers of neuroprotective and neuroreparative molecules and facilitate functional integration between implanted and patient cells», adds UCM’s researcher and director of the study, published in the Journal of Neural Engineering .

One more step in a problem with more than 196 million affected

To build this artificial retina, researchers have developed silk fibroin films with mechanical characteristics similar to Bruch’s membrane — the layer of cells that supports the neural retina. Then, they have biofunctionalized them so that retinal cells could adhere, and on them they have grown epithelial and neural cells. Finally, they have carried out an in vitro study of the structural and functional characteristics of the biohybrid.

Age-Related Macular Degeneration (AMD) is a neurodegenerative disease that causes a progressive loss of central vision and even blindness in its most advanced stage. Triggered by heterogeneous, complex and still poorly understood mechanisms, it is the leading cause of irreversible vision loss in people over 65 years of age and affects more than 196 million people worldwide.

AMD is an incurable disease, and current treatments can only alleviate symptoms and slow down the progression of the disease. «This research is an important step towards solving the problem of blindness faced by AMD patients», concludes Panetsos.

###

In addition to UCM and IdISSC, participated among others the Center for Biomedical Technology of the Polytechnic University of Madrid, La Paz University Hospital, CIBER for Bioengineering, Biomaterials and Nanomedicine, University of Kiel (Germany), Tufts University (USA) and the spin-off Silk Biomed SL

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.